The relationship between growth differentiation factor-15 and testosterone hormone level in prostate cancer patients

Prostate cancer (PCa) is a common non-skin malignancy disease that frequently causes death males and the burden of this cancer continuously elevating in many countries and especially Asian. Hence the need to find prognostic markers to predict aggressiveness, patients' outcome, and efficacy of treatment are raising.We analyzed serum and clinical data from 100 case divided in to 70 men as patient group and 30 men as control group . Serum growth differentiation factor 15 (GDF15), prostate specific antigen (PSA), total serum testosterone, follicle-stimulating hormone (FSH) and C‑reactive protein (CRP) were assayed by BioTek Elisa and Roche Cobas c 311. In Serum PCa patients with continuously disease progression were Levels of GDF-15 elevated.There was a significant increase PSA levels with prostate cancer patients with old injury but observed a trend to tiny depression in levels of serum total Testosterone and FSH. Concerning to the Pearson Scale there were positive significantly (P < 0.0023) correlated between serum GDF-15 with Prostate-specific antigen (PSA) levels. In addition, there were a positive significantly (P <0.002) correlated to the duration of the disease with the level of C-reactive protein (CRP) in serum. In our conclusion, a strong correlation was observed between increasing (GDF-15), PSA and body mass index (BMI) with PCa risk. Also, Prostate cancer patients was related to depress FSH and total testosterone levels. The present thesis reinforce the use of GDF15 and PSA examinations as prognostic biomarkers in PCa and in determining disease progression. Keywords: Prostate Cancer; GDF-15; Total Testosterone; PSA; CRP; FSH; Roche Cobas c 311; Prognostic marker